Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Fan, Shengtao; Xiao, Kang; Li, Dandan; Zhao, Heng; Zhang, Jingjing; Yu, Li; Chang, Penglan; Zhu, Shuangli; Xu, Xingli; Liao, Yun; Ji, Tianjiao; Jiang, Guorun; Yan, Dongmei; Zeng, Fengyuan; Duan, Suqin; Xia, Baicheng; Wang, Lichun; Yang, Fengmei; He, Zhanlong; Song, Yang; Cui, Pingfang; Li, Xiaolei; Zhang, Yaxing; Zheng, Bangyi; Zhang, Ying; Xu, Wenbo; Li, Qihan
• Is Part Of: Emerging microbes & infections. Volume 11:Issue 1(2022)
• Page Start: 212
• Page End: 226
• Publication Date: 2022-12-31
• Subjects: SARS-CoV-2 -- variants -- intradermal administration -- vaccine; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2021.2021807
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: The recent emergence of COVID-19 variants has necessitated the development of new vaccines that stimulate the formation of high levels of neutralizing antibodies against S antigen variants. A new strategy involves the intradermal administration of heterologous vaccines composed of one or two doses of inactivated vaccine and a booster dose with the mutated S1 protein (K-S). Such vaccines improve the immune efficacy by increasing the neutralizing antibody titers and promoting specific T cell responses against five variants of the RBD protein. A viral challenge test with the B.1.617.2 (Delta) variant confirmed that both administration schedules (i.e. "1 + 1" and "2 + 1") ensured protection against this strain. These results suggest that the aforementioned strategy is effective for protecting against new variants and enhances the anamnestic immune response in the immunized population.